Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1096 participants.
Also called NCT07241520
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,096 participants
- Registry
-
NCT07241520
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07241520. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-08 (actual); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
- Acronym
- SAIL
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- SHPL-49 Injection
- Intervention (Drug)
- Placebo Injection
- Lead sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Collaborator
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct07241520- Content hash
846b60f8bb74103db9610593efa2a6e9e95328bd3627e7fd09fe1870462d5939